CA
NZ
UK
AU
IND
US
…
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Integra LifeSciences makes medical devices and biologic products for neurosurgery, reconstructive and general surgery, wound care and orthopedics, including procedure-driven consumables and regenerative therapies. Long-term growth may be supported by aging populations, rising demand for advanced wound care and neurosurgical procedures, geographic expansion and incremental product innovation.
Key risks include regulatory and reimbursement changes, competition from larger medtech companies, dependence on procedure volumes and concentration in a few higher-revenue products.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 213.89M | 214.68M | 93.52M | 60.10M | 57.40M |
| Net income | 180.55M | 169.07M | 133.89M | 50.20M | 60.80M |
| Selling general administrative | 616.32M | 637.45M | 594.53M | 687.60M | 690.75M |
| Gross profit | 970.31M | 944.64M | 851.03M | 952.88M | 900.95M |
| Reconciled depreciation | 118.30M | 16.91M | 116.03M | 109.46M | 110.73M |
| Ebit | 238.92M | 197.23M | 151.37M | 178.98M | 122.09M |
| Ebitda | 276.73M | 240.19M | 192.86M | 206.00M | 143.25M |
| Depreciation and amortization | 37.81M | 42.96M | 41.49M | 27.03M | 21.16M |
| Non operating income net other | 24.57M | 67.84M | 13.73M | 20.30M | 11.09M |
| Operating income | 238.92M | 197.23M | 151.37M | 178.98M | 111.00M |
| Other operating expenses | 1318.75M | 1345.22M | 1220.50M | 1358.88M | 1361.44M |
| Interest expense | 49.59M | 50.40M | 71.58M | 53.96M | 64.68M |
| Tax provision | 33.34M | 45.60M | -40.37M | 9.90M | -3.40M |
| Interest income | 11.92M | 6.74M | 9.30M | 10.78M | 2.80M |
| Net interest income | -37.68M | -43.66M | -62.28M | -43.18M | -61.88M |
| Non recurring | - | - | - | 64.92M | - |
| Income tax expense | 33.34M | 45.60M | -40.37M | 9.90M | -3.40M |
| Total revenue | 1557.67M | 1542.45M | 1371.87M | 1517.56M | 1472.44M |
| Total operating expenses | 731.39M | 747.41M | 699.66M | 794.20M | 789.95M |
| Cost of revenue | 587.36M | 597.81M | 520.83M | 564.68M | 571.50M |
| Total other income expense net | -25.03M | 17.45M | -57.85M | -118.87M | 8.29M |
| Net income from continuing ops | 180.55M | 169.07M | 133.89M | 50.20M | 60.80M |
| Net income applicable to common shares | 180.55M | 169.07M | 133.89M | 50.20M | 60.80M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3781.99M | 3889.76M | 3782.38M | 3615.14M | 3303.24M |
| Intangible assets | 1067.83M | 1126.61M | 1145.57M | 989.44M | 1031.59M |
| Other current assets | 100.00M | 116.79M | 91.05M | 231.39M | 67.91M |
| Total liab | 2194.10M | 2085.36M | 2097.58M | 2100.27M | 1886.50M |
| Total stockholder equity | 1587.88M | 1804.40M | 1684.80M | 1514.87M | 1416.74M |
| Deferred long term liab | - | 63.34M | 45.79M | 16.19M | 36.55M |
| Other current liab | 176.30M | 158.80M | 213.11M | 182.06M | 156.19M |
| Common stock | 0.91M | 0.91M | 0.90M | 0.89M | 0.89M |
| Capital stock | 0.91M | 0.91M | 0.90M | 0.89M | 0.89M |
| Retained earnings | 946.86M | 879.12M | 698.57M | 532.26M | 398.57M |
| Other liab | - | 201.84M | 135.90M | 131.18M | 116.11M |
| Good will | 1055.46M | 1038.88M | 1013.46M | 932.37M | 954.28M |
| Other assets | - | 63.15M | 3782.38M | 168.60M | 27.27M |
| Cash | 276.40M | 456.66M | 513.45M | 470.17M | 198.91M |
| Total current liabilities | 306.98M | 320.91M | 340.02M | 401.01M | 331.31M |
| Current deferred revenue | 8.54M | 7.25M | 5.29M | 5.28M | 4.77M |
| Net debt | 1405.28M | 1158.70M | 1137.84M | 1185.24M | 1258.91M |
| Short term debt | 29.82M | 52.75M | 59.77M | 159.07M | 57.25M |
| Short long term debt | 14.53M | 38.12M | 45.00M | 146.25M | 45.00M |
| Short long term debt total | 1681.68M | 1615.36M | 1651.29M | 1655.41M | 1457.82M |
| Other stockholder equity | 655.22M | 914.12M | 1030.49M | 1055.77M | 1093.68M |
| Property plant equipment | - | 311.30M | 311.70M | 287.53M | 337.40M |
| Total current assets | 1058.04M | 1161.50M | 1153.72M | 1237.20M | 858.17M |
| Net tangible assets | - | -361.09M | -474.23M | -406.94M | -569.13M |
| Short term investments | 32.69M | - | - | - | - |
| Net receivables | 259.33M | 263.46M | 231.83M | 225.53M | 275.30M |
| Long term debt | 1485.02M | 1300.49M | 1388.68M | 1408.22M | 1198.56M |
| Inventory | 389.61M | 324.58M | 317.39M | 310.12M | 316.05M |
| Accounts payable | 92.33M | 102.10M | 61.84M | 54.61M | 113.09M |
| Accumulated other comprehensive income | -15.11M | 10.27M | -45.16M | -74.06M | -76.40M |
| Common stock total equity | - | 0.91M | 0.90M | 0.89M | 0.89M |
| Retained earnings total equity | - | 879.12M | 698.57M | 532.26M | 398.57M |
| Treasury stock | - | -362.86M | -234.45M | -235.14M | -119.94M |
| Non currrent assets other | 26.01M | -510.15M | 16.44M | 11.28M | 14.64M |
| Non current assets total | 2723.95M | 2728.26M | 2628.67M | 2377.93M | 2445.07M |
| Capital lease obligations | 182.13M | 172.04M | 105.10M | 100.94M | 109.76M |
| Long term debt total | - | 1300.49M | 1388.68M | 1408.22M | 1198.56M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 4.91M | 0.08M | -7.84M | 2.34M | 0.91M |
| Change to liabilities | 12.90M | 18.76M | -60.40M | 12.61M | 3.98M |
| Total cashflows from investing activities | -58.58M | -161.44M | -68.07M | -162.67M | -49.70M |
| Net borrowings | -107.80M | -100.25M | 281.15M | -9.20M | -493.84M |
| Total cash from financing activities | -251.95M | -98.23M | 121.62M | 64.46M | -180.87M |
| Change to operating activities | 1.99M | -27.38M | 12.48M | 24.17M | 5.38M |
| Net income | 180.55M | 169.07M | 133.89M | 50.20M | 60.80M |
| Change in cash | -56.79M | 43.28M | 271.25M | 60.07M | -36.10M |
| Begin period cash flow | 513.45M | 470.17M | 198.91M | 138.84M | 174.94M |
| End period cash flow | 456.66M | 513.45M | 470.17M | 198.91M | 138.84M |
| Total cash from operating activities | 264.47M | 312.43M | 203.83M | 373.68M | 199.68M |
| Issuance of capital stock | - | - | 0.00M | 0.00M | 349.59M |
| Depreciation | 118.30M | 119.84M | 116.03M | 109.46M | 110.73M |
| Other cashflows from investing activities | -21.15M | -161.44M | -21.34M | -95.47M | 27.13M |
| Dividends paid | - | - | 44.56M | - | - |
| Change to inventory | -29.12M | 5.37M | -48.35M | -43.31M | 8.30M |
| Change to account receivables | -33.91M | 7.26M | 52.10M | -9.43M | -17.02M |
| Sale purchase of stock | -125.00M | 6.82M | -100.00M | 6.95M | 358.98M |
| Other cashflows from financing activities | 21.60M | 27.27M | 766.87M | 310.56M | 129.54M |
| Change to netincome | 2.19M | 126.44M | -43.60M | 10.91M | 20.14M |
| Capital expenditures | 47.09M | 48.08M | 63.89M | 134.53M | 77.74M |
| Change receivables | -33.91M | 7.26M | 52.10M | -9.43M | -17.02M |
| Cash flows other operating | 13.55M | -0.14M | 38.73M | 95.60M | 6.49M |
| Exchange rate changes | - | - | - | - | -5.20M |
| Cash and cash equivalents changes | -46.06M | 52.76M | 257.38M | 60.00M | -36.10M |
| Change in working capital | -39.42M | 18.16M | -41.31M | -14.51M | 1.75M |
| Stock based compensation | 27.73M | 36.21M | 19.59M | 21.25M | 20.78M |
| Other non cash items | -18.10M | -28.10M | 39.77M | 226.32M | 13.81M |
| Free cash flow | 217.38M | 264.35M | 139.94M | 239.15M | 121.94M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IART Integra LifeSciences Holdings |
-0.37 2.88% |
12.46 | 55.52 | 9.94 | 1.67 | 1.62 | 2.56 | 15.44 |
| ABT Abbott Laboratories |
1.38 1.32% |
105.95 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.32 0.33% |
96.79 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-19.22 6.17% |
292.53 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jan De Witte | Pres, CEO & Director | 1964 |
| Ms. Carrie L. Anderson | Exec. VP, CFO & Treasurer | 1969 |
| Mr. Robert T. Davis Jr. | Exec. VP & Pres of Tissue Technologies | 1959 |
| Mr. Michael J. McBreen | Exec. VP & Pres of Codman Specialty Surgical | 1966 |
| Mr. Jeffrey Mosebrook | Sr. VP, Principal Accounting Officer & Corp. Controller | 1976 |
| Dr. Kenneth E. Burhop Ph.D. | Corp. VP & Chief Scientific Officer | 1954 |
| Mr. William Compton | Chief Information Officer & Corp. VP | NA |
| Mr. Eric Ian Schwartz | Exec. VP, Chief Legal Officer & Sec. | 1969 |
| Laurene Isip | VP of Global Corp. Communications & PR | NA |
| Ms. Maria Platsis | Sr. VP of Corp. Devel. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-2.00%
Communication Services
-0.40%
Consumer Cyclical
-0.24%
Consumer Defensive
+0.34%
Energy
-0.17%
Financial Services
-0.79%
Financials
+2.35%
Healthcare
-1.57%
Industrials
-1.05%
Real Estate
-0.31%
Technology
-3.26%
Utilities
-0.30%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...